ENGN enGene Holdings Inc.

NASDAQ
$1.98

enGene Holdings Inc. (ENGN) is expected to report earnings on December 8, 2026, before the market open. The consensus earnings estimate is a loss of $0.46 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +8.8% since its last earnings release on September 8, 2026.

enGene Reported In-line with Estimates
Tuesday, September 8, 2026 · 7:30 AM ET
Earnings Date
4th Quarter, Oct 2026
Dec 8
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.46) (GAAP)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.94

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About enGene Holdings Inc.

enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.